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DOI 10.1016/j.ccr.2011.03.023SUMMARYThe human gene Ptpn11, which encodes the tyrosine phosphatase Shp2, may act as a proto-oncogene
because dominantly activating mutations have been detected in several types of leukemia. Herein we report
a tumor-suppressor function of Shp2. Hepatocyte-specific deletion of Shp2 promotes inflammatory signaling
through the Stat3 pathway and hepatic inflammation/necrosis, resulting in regenerative hyperplasia and
development of tumors in aged mice. Furthermore, Shp2 ablation dramatically enhanced diethylnitrosamine
(DEN)-induced hepatocellular carcinoma (HCC) development, which was abolished by concurrent deletion of
Shp2 and Stat3 in hepatocytes. Decreased Shp2 expression was detected in a subfraction of human HCC
specimens. Thus, in contrast to the leukemogenic effect of dominant-active mutants, Ptpn11/Shp2 has
a tumor-suppressor function in liver.INTRODUCTION
The advancement in understanding the molecular basis of
carcinogenesis has benefited tremendously from genetic and
functional analyses of oncogenes and tumor-suppressor genes
(Levine and Puzio-Kuter, 2010; Weinberg, 1995). In conven-
tional view the genesis of cancer can be triggered by dominant
gain-of-function mutations in proto-oncogenes and recessive
loss-of-function mutations in tumor-suppressor genes or anti-
oncogenes (Bishop, 1991). Studies initiated on v-Src and
c-Src have revealed essential roles of tyrosine kinases in regu-
lation of cell proliferation, and their oncogenic activation in
promoting malignant transformation (Blume-Jensen and
Hunter, 2001; Sefton and Hunter, 1986). This conception has
naturally predicted tyrosine phosphatases functioning as tumorSignificance
Genetic and functional analyses of oncogenes and tumor sup
advance in understanding themolecular basis of carcinogenes
tor tyrosine phosphatase Shp2 has been identified as a proto
dominant-active mutations of Ptpn11 in leukemias. However
Ptpn11/Shp2 in liver malignancy. Shp2 normally acts to sup
inflammatory signaling. This study provides insight into the msuppressors. Indeed, genetic data have implicated loss or inac-
tivation of tyrosine phosphatase genes in cancer development
and metastasis (Revillion et al., 2009; Sun et al., 2011; Veeriah
et al., 2009; Wang et al., 2004).
Interestingly, recent work has led to identification of Ptpn11/
Shp2 as a proto-oncogene (Chan and Feng, 2007; Tartaglia
et al., 2003). Shp2 is an intracellular tyrosine phosphatase with
two Src-homology 2 (SH2) domains that acts to promote activa-
tion of the Ras-Erk pathway by growth factors, cytokines, and
hormones (Lai et al., 2004; Neel et al., 2003). Autosomal-domi-
nant mutations in the human gene Ptpn11 have been detected
in nearly 50% of patients with Noonan syndrome who have
higher risk of suffering juvenile myelomonocytic leukemia
(JMML), and somatic mutations constitutively activating Shp2
have also been found in several types of leukemias (Tartagliapressor genes have contributed tremendously to the rapid
is. Interestingly, thePtpn11 gene that encodes the nonrecep-
-oncogene based on the detection of inherited and somatic
, data presented here suggest a tumor-inhibiting effect of
press hepatocellular carcinogenesis via downregulation of
olecular mechanism linking inflammation and cancer.
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Identification of Shp2 as a Tumor Suppressorand Gelb, 2005). Overexpression of Shp2 was detected in
leukemia and breast cancer cell lines and patient samples (Xu
et al., 2005; Zhou et al., 2008). In previous work we generated
a hepatocyte-specific Shp2 knockout (Shp2hep/) mouse
model, and found that Shp2 deletion suppressed Erk signal
and hepatocyte proliferation following partial hepatectomy
(Bard-Chapeau et al., 2006). The effect of Shp2 in amplification
of proliferative signal in hepatocytes is consistent with a body
of literature documenting a positive role of this phosphatase in
cellular responses to mitogenic stimuli (Lai et al., 2004; Neel
et al., 2003).
The present study is designed to investigate the possible
tumor-suppressor function of Ptpn11/Shp2 in liver.RESULTS
Shp2hep–/– Mice Developed Hepatic Inflammation
and Necrosis
Shp2 was deleted in hepatocytes in Shp2hep/ mice that
were generated by crossing Shp2flox/flox mice with Albumin-Cre
transgenic mice (Bard-Chapeau et al., 2006). Shp2hep/ mice
were born with the expected frequency and were morphologi-
cally indistinguishable from their control littermates. The body
weights were similar between Shp2hep/ and control animals
at 2 months of age in fed or fasting state (see Figure S1A
available online). There was also no difference between control
and Shp2hep/ young mice in the ratio of liver weight to body
weight (Figure S1B). Serum levels of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) were significantly
higher in Shp2hep/ mice than that in controls (Figure 1A).
Macroscopic examination revealed one or several foci of pallor
noticeable on the liver surface in 34% of dissected Shp2hep/
animals (n = 21) (Figure 1B). Hematoxylin and eosin staining
(H&E) of liver sections showed large areas of parenchymal
necrosis (Figure 1C). Smaller focal areas of parenchymal
necrosis were also detected (Figures 1D and 1E). Necrosis was
observed in 47% of Shp2hep/ animals (n = 21) in contrast to
0% of control mice (n = 11). TUNEL assay revealed no significant
difference in apoptosis between control and Shp2hep/ livers
(data not shown). A large proportion (93%) of Shp2hep/ livers
(n = 21) contained areas with infiltrate of inflammatory cells
(Figures 1D–1F), which appeared to concentrate around the
portal triads with extension into the parenchyma. Inflammatory
cells were visible outside, around, or inside the necrotic areas.
Necrotic zones were always associated with inflammatory
cells (Figures 1C–1E), whereas inflammation was occasionally
observed without necrosis (Figure 1F). Signs of fibrosis were
found at the portal triads, but not near the necrosis or into
parenchyma, as revealed by trichrome staining (Figures 1G
and 1H).
We detected significantly increased amounts of circulating
IL-6 in Shp2hep/ animals, among 11 cytokines examined
(Figure 1I). We then examined local expression of cytokine and
inflammatory genes in the liver by real-time RT-PCR (Figure 1J).
Hepatic expression of IL-6, TNFa, and SAP (serum amyloid-P)
mRNAs was remarkably elevated in Shp2hep/ livers, whereas
transcripts of hepatocyte growth factor (HGF) and Bcl-xl were
not changed (Figure 1J).630 Cancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc.Enhanced Hepatic and Systemic Inflammatory
Responses to LPS in Shp2hep–/– Animals
To define hepatic inflammatory responses in Shp2hep/ mice,
we assessed induction of liver damage by lipopolysaccharides
(LPS) challenge. Intraperitoneal LPS injection elicited a stronger
liver damage response in Shp2hep/ mice than in controls, as
indicated by higher serum ALT levels (Figure 2A). We also
measured the ratio of spleen versus body weight to assess
systemic inflammatory response. Shp2hep/ animals displayed
an increase of 130% in their spleen size 14 days after LPS
challenge as compared to 98% for control animals (Figure 2B),
suggesting an aggravated immune/inflammatory response
when Shp2 was removed in hepatocytes. H&E of liver sections
also revealed increased inflammatory cell infiltration into hepatic
parenchyma (Figure 2C).
We measured circulating levels of inflammatory cytokines at
different time points following LPS injection (Figures 2D and
2E), and detected similarly increased levels for IFNg, RANTES,
IL-12, IL-1b, and IL-10 in control and Shp2hep/ mice (Fig-
ure 2E). However, higher levels of IL-6 and TNFa were detected
inShp2hep/ than in control mice after LPS injection, suggesting
an enhanced IL-6 production in Shp2hep/ animals (Figure 2D).
Shp2 Deficiency in Hepatocytes Leads to Enhanced
Inflammatory Signaling in the Liver
To dissect intracellular signaling events, we prepared liver
extracts after LPS injection into vena cava for 5 min or intraper-
itoneally for longer time periods. LPS-stimulated pY-Stat3 and
pY-Stat1 signals were increased and prolonged in Shp2hep/
liver compared to control (Figures 3A and 3B). Degradation of
IkBa was potentiated at 1 hr after LPS challenge, p-Erk1/2 and
p-p38 signals were impaired, whereas p-Jnk1/2 levels were
elevated at 1 and 3 hr in mutant samples (Figures 3A and 3B).
To directly evaluate IL-6 signaling in the liver, we injected re-
combinant IL-6 through the portal vein (Figure 3C). Shp2hep/
livers responded more potently than controls in induction of
pY-Stat3 and pY-Stat1 signals. Quantitative analysis of four
mice in each genotype revealed a 2.1-fold increase of IL-
6-induced pY-Stat3 signal in Shp2hep/ livers over controls.
In contrast, Shp2 deletion suppressed Erk activation by IL-6,
indicating a unique negative role of Shp2 in regulating the IL-6/
Stat3 pathway in the liver.
Shp2 Removal Promotes Inflammatory Signaling
through Stat3 in Hepatocytes
The hepatic inflammatory response involves communication of
different cell types such as hepatocytes and Kupffer cells. In
Shp2hep/ mice, Shp2/Ptpn11 was deleted in hepatocytes
only, due to cell type-specific Cre expression directed by the
Albumin promoter. To determine the cell-intrinsic effect of
Shp2 ablation, we isolated primary hepatocytes for treatment
with LPS (5 mg/ml) in vitro. As shown in Figure 3D, Shp2 deletion
had no effect on LPS stimulation of IkBa degradation (hence
NF-kB activation) in hepatocytes. However, LPS-induced
pY-Stat3 signal was enhanced and prolonged in Shp2-deficient
hepatocytes. LPS-stimulated p-Erk and p-p38 signals were
impaired, whereas p-Jnk levels were elevated in mutant,
compared to control cells (Figure 3D). Akt was mildly stimulated
by LPS in hepatocytes with higher basal and activated levels
Figure 1. Hepatic Damage and Inflammation in
Shp2hep–/– Mice
(A) Circulating blood levels of AST and ALTwere quantified
in control or Shp2hep/ mice at indicated ages (n = 4–8;
*p < 0.05, **p < 0.01 for WT versus Shp2hep/).
(B) Gross appearance of the right lobe of aShp2hep/ liver
showing pale acellular regions.
(C) H&E of aShp2hep/ liver section showed inflammation
and macroscopic necrosis.
(D) H&E showed a small necrotic area surrounded and
infiltrated by inflammatory cells inShp2hep/ liver section.
In (D)–(H) arrows indicate portal triads and diamond arrow
shows central vein.
(E) A necrosis area was surrounded by inflammatory infil-
trates in H&E Shp2hep/ liver section.
(F) H&E showed severe inflammatory infiltrates in
Shp2hep/ liver.
(G and H) Trichrome staining showed low and high levels
of collagen secret surrounding the portal triad of control
(G) and Shp2hep/ (H) liver sections, respectively.
(I) Circulating blood levels of inflammatory cytokines were
quantified at 2–3 months of age (n = 7–18; *p < 0.05).
(J) Hepatic gene expression of IL-6, TNF, Bcl-xl, and HGF
was assessed by qRT-PCR of total mRNAs isolated from
2- to 3-month-old mouse livers. The results were the
average of three mice, and absolute mRNA values were
determined and normalized to cyclophilin. Data were ex-
pressed as mean ± SEM.
See also Figure S1.
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Stat3, Jnk, and Akt, while positively modulating Erk and p38
induction in hepatocytes by LPS (Figure 3D).Cancer Cell 19Consistently, pY-Stat3 signal was enhanced
and sustained in Shp2/ hepatocytes following
IL-6 treatment, whereas no significant change
was detected for Stat1. IL-6-induced p-Erk
and p-p38 levels were reduced, and p-Akt
signal was elevated in mutant cells compared
to controls (Figure 3E). We simultaneously
measured LPS-induced cytokine secretion by
hepatocytes in the culture medium (Figure 3F).
LPS stimulation caused higher IL-6 secretion
by Shp2-deficient hepatocytes, whereas
comparable secretion levels were observed in
control and mutant hepatocytes for several
other cytokines, with mild increase of IL-12
and IL-10 detected at 24 hr of LPS stimulation
(Figure 3G).
Shp2 Ablation Leads to Development
of Hepatocellular Tumor in Aged Animals
We followed Shp2hep/ mice longitudinally to
assess their phenotype later in life and detected
efficient Shp2 deletion at 1 year of age (Fig-
ure 4A). Aged Shp2hep/ mice became leaner
by 10.7% for male and 14.9% for female mice,
with a significant decrease of their body weights
at 1 year (Figure S2A), although their livers were
at normal size (Figure S2B). Beginning at
5 months of age, microscopic foci resemblingregenerative foci were noticeable in the liver of Shp2hep/
animals. Nodular regenerative hyperplasia was detected in
Shp2hep/ animals from 8 months of age. At 12–18 months of, 629–639, May 17, 2011 ª2011 Elsevier Inc. 631
Figure 2. Hypersensitivity to LPS in
Shp2hep–/– Animals
(A) Circulating blood levels of ALT were quantified
in WT and Shp2hep/ mice at indicated time
points after LPS injection (n = 3–4).
(B) Spleen weight was measured and normalized
to body weight at several time points after LPS
challenge (n = 5).
(C) Graphic representation of hepatic inflammation
levels. Values from 0 to 4 were given to each H&E
slide according to the level of infiltration by
inflammatory cells. An average was calculated
from five to ten mice of each genotype.
(D) Circulating serum levels of TNFa and IL-6 were
determined at indicated time points after LPS
injection (n = 3–7; *p < 0.05 for WT versus
Shp2hep/).
(E) Serum levels of IFNg, RANTES, IL-12, IL-1b,
and IL-10 were quantified at indicated time points
after LPS administration (n = 3–7). Data are ex-
pressed as mean ± SEM.
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0.1–1 cm in diameter were frequently detected in Shp2hep/
mice (13 of 19) under both capsular and cut surface, which
was not detectable in control animals (0 of 16). The tumors
bulged from the liver surface and were often paler than the
hepatic parenchyma (Figure 4B), but sometimes darker or red
when accompanied by bleeding. On liver sections the tumors632 Cancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc.were unencapsulated, quite well de-
limited, showing expanding masses of
hepatocytes, and positively stained with
reticulin (Figure 4C).
The development of hepatocellular
adenoma suggests increased and
neoplastic proliferation of hepatocytes in
the absence of Shp2, and we performed
bromodeoxyuridine (BrdU) incorporation
assay to quantify cell proliferation rate.
BrdU+ hepatocyte number was increased
in Shp2hep/ animals as compared to
littermate controls (Figure 4D). We found
an average of 7.8% BrdU+ cells in control
animals (n = 5) versus 25.4% in the
abnormal tissue of Shp2hep/ animals
(n = 10), a significant increase of hepato-
cyte proliferation. Histological analysis of
hepatic parenchyma revealed signs of
regenerative hyperplasia with 13 of 19
Shp2hep/ livers having nodule forma-
tion (Figures 4E–4G). In most cases the
lobular architecture was distorted by the
development of hyperplastic hepatocyte
plates (Figures 4E–4G). The space
between hepatocytes was strikingly
reduced inside the nodules (Figure 4E).
TUNEL assay performed on liver sections
revealed low number of apoptotic hepa-
tocytes in Shp2hep/ liver parenchyma
(Figure 4H). However, inside of or surrounding the hyperplastic
nodules, massive hepatocyte degeneration was usually found,
in association with vacuoles containing eosinophilic material
(Figures 4G and 4H). This explains the high levels of serum ALT
and AST in 12- to 18-month-old Shp2hep/ mice despite the
absence of hepatic necrosis at that age (Figure 1A). Although
parenchymal necrosis and inflammation were not detected,
Figure 3. Altered Hepatic LPS and IL-6 Signaling Events In Vivo and In Vitro
(A) Mice were injected with LPS, and pY-Stat1, pY-Stat3, p-Jnk1/2, p-Erk1/2, and p-p38 MAPK were assessed by immunoblotting with their protein levels as
controls. IkBa degradation was assessed using Erk2 protein as control.
(B) The phospho-signals were quantified and normalized against total liver protein amounts. IkBa protein amounts were normalized against Erk2 The relative
signal levels were determined by setting the value of the control at 1 hr as 1 U (n = 3–6; *p < 0.05, **p < 0.01 for WT versus Shp2hep/).
(C) Immunoblotting of liver lysates was performed 5 min after injection of IL-6 (5 mg) into portal vein. pY-Stat3 and pS-Stat3, and p-Erk levels were assessed.
(D and E) pY-Stat3 and pS-Stat3, p-Jnk1/2, p-Akt (Ser473), p-Erk, p-p38 MAPK were assessed by immunoblot analysis with the respective protein levels as
control. The IkBa degradation was compared to Erk2 protein level.
(F and G) Amounts of inflammatory cytokines were quantified in supernatants fromWT and Shp2hep/ hepatocytes (n = 3). Data are expressed as mean ± SEM.
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consisting of mononuclear inflammatory cells (Figure 4E). To
determine altered signaling events underlying development of
hepatic adenoma in aged Shp2hep/ animals, we evaluated
the activation status of several signaling molecules (Figure 4I).
Elevated tyrosine phosphorylation levels of Stat3 were detected
in two of four tumor samples. Efficient Shp2 deletionwas steadily
detected in adenoma cells, suggesting that escaped deletion ofShp2flox/flox cells was not the cause of adenoma development/
progression in Shp2hep/ mice (Figure 4I).
To explore the possible tumor-suppressing role of Shp2 in
human hepatocellular carcinoma (HCC) development, we
screened 104 HCC specimens for Shp2 expression and de-
tected dramatically decreased Shp2 protein levels in HCC in
12 samples, as compared to their surrounding tissue (Figure 4J).
This observation suggests that Shp2 deficiency is likely one ofCancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc. 633
Figure 4. Spontaneous Development of Hepato-
cellular Adenoma in Aged Shp2hep–/– Mice
(A) Immunoblot analysis of Shp2 protein levels in the liver
andmuscle isolated from young or oldWT and Shp2hep/
mice.
(B) Macroscopic view of hepatic adenomas that bulged
from the surface of Shp2hep/ liver and appeared pale
compared to the hepatic parenchyma.
(C) Reticulin staining of an adenoma.
(D) Hepatocyte proliferation in Shp2hep/ (left panel) and
WT (right panel) aged littermate mice. BrdU-positive cells
are green, and DAPI-stained nuclei are red.
(E) H&E of an adenoma.
(F) H&E showed nodular regenerative hyperplasia.
(G) H&E showed hepatocyte degeneration, associated
with vacuoles containing eosinophilic material at the
periphery of adenoma.
(H) TUNEL assay revealed an area of focal apoptosis
(dark-brown nuclei) in the liver parenchyma. Slides were
counterstained with methyl green.
(I) pY-Stat3 levels in WT, tumoral Shp2hep/ parenchyma
(T), and nontumoral (N) parenchyma of 18-month-old
mice, as assessed by immunoblotting of tissue extracts.
(J) Human HCC specimens and corresponding
surrounding tissue (ST) from the same patient were
immunostained for Shp2. Shown here are three represen-
tative sampleswith Shp2 contents lower inHCC than in ST.
See also Figure S2.
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sion of some human HCCs.
Stat3 Is Required for Promotion of HCC Development
by Shp2 Deletion
To further determine the anti-oncogenic action of Shp2 in
liver malignancy, we evaluated the effect of Shp2 removal on
HCC in mice induced by chemical carcinogen. Control and
Shp2hep/micewere injectedwith a single dose of diethylnitros-
amine (DEN) on postnatal day 15, and animals were dissected
after 8 months to examine HCC incidences, as described previ-634 Cancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc.ously (He et al., 2010; Maeda et al., 2005).
All the male animals in both control and
Shp2hep/ groups developed visible hepatic
tumor foci (Figure 5A). However, hepatocyte-
specific deletion of Shp2 dramatically increased
the number and sizes of liver tumors (Figures
5A–5C). We also used liver/body weight ratio to
determine the tumor burden in DEN-treated
animals. As shown in Figure 5D, the ratio
increased almost 1-fold in Shp2hep/ animals,
compared to controls. Consistent with the
observation of spontaneous tumor development
in aged Shp2hep/ mice, these results strongly
support a notion thatShp2 is a tumor suppressor
in HCCs elicited by chemical carcinogen.
We detected elevated pY-Stat3 levels in
most of the tumor and surrounding tissues in
Shp2hep/ livers, as compared to controls (Fig-
ure 5F), suggesting constitutive activation of the
Stat3 pathway in HCCs devoid of Shp2. Thisobservation is also consistent with results shown in Figure 3
that Shp2 removal resulted in enhanced inflammatory signaling
through Stat3. To determine the role of Stat3 in hepatocarcino-
genesis enhanced by Shp2 deficiency, we generated hepato-
cyte-specific Shp2/Stat3 double knockout (DKO) mice and
examined DEN-induced HCCs. Interestingly, simultaneous dele-
tion of Shp2 and Stat3 in hepatocytes significantly suppressed
the promoting effect of Shp2 ablation on HCC development
(Figures 5A–5E). Although the tumor frequency and sizes were
still higher in DKO than in control animals, there was no differ-
ence between DKO and Stat3hep/ male mice. These data
Figure 5. Enhanced HCC Development in Shp2hep–/– Livers Is Compromised by Additional Deletion of Stat3
(A) Gross appearances of representative livers with tumors in control (WT), Shp2hep/, Shp2/Stat3hep/ (DKO), and Stat3hep/ male mice.
(B) Liver tumor numbers were compared among WT, Shp2hep/, Stat3hep/, and DKO mice (male, n = 5–13).
(C) Average maximal diameters of tumors were measured and compared among WT, Shp2hep/, Stat3hep/, and DKO livers (male, n = 5–13).
(D) The liver/body weight ratios were determined and compared among the four groups of mice (male, n = 5–13). Data were expressed as mean ± SEM. *p < 0.05;
**p < 0.01; ***p < 0.001.
(E) Tumor incidences were determined in WT, Shp2hep/, Stat3hep/, and DKO female mice (n = 6–13).
(F) Immunoblotting was performed to evaluate pY-Stat3 levels in tumors (T) and surrounding hepatic tissues (N).
(G) Deletion of Shp2 and/or Stat3 in Shp2hep/, Stat3hep/, or DKO livers was evaluated by PCR analysis of genomic DNA extracted from tumor or surrounding
liver tissues.
(H) Immunoblotting was performed for protein extracts from tumor (T) and surrounding liver tissues (N) to determine Shp2 and/or Stat3 removal.
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completely the impact of Shp2 deficiency on HCC because the
tumor occurrence in DKO mice represented the effect elicited
by Stat3 ablation alone. Similar results were obtained in female
animals (Figure 5E), with over 70% of Shp2hep/ female mice
developing visible foci, 6-fold higher than controls; the tumor
incidence was reduced by 50% in DKO and Stat3hep/ femalemice. Of note, PCR analysis of genomic DNA and immunoblot
analysis of protein contents confirmed efficient deletion of
Shp2 and/or Stat3 in tumors and normal hepatic tissues in
respective animals (Figures 5G and 5H), as genotyped by PCR
analysis of tail DNA. In aggregate these results show that Shp2
removal exacerbates DEN-induced HCC development, which
requires Stat3. However, deletion of Stat3 in hepatocytes didCancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc. 635
Figure 6. Increased Inflammation in Shp2hep–/– Livers Is Reduced by Combined Deletion of Shp2 and Stat3
(A–D) Representative H&E of tumor samples showed typical trabecular structures in control and Stat3hep/ livers, but not in Shp2hep/ and DKO livers,
and reduced size of eosinophilic vacuoles of degeneration in DKO liver.
(E–H) Representative H&E of liver samples showed infiltrate of inflammatory cells in portal triads ofShp2hep/ and DKO livers, and fat droplets inStat3hep/ liver.
(I) Serum ALT levels were measured in the four groups of mice.
(J and K) IL-6 and TNFa levels in liver extracts were measured by ELISA.
(L and M) qRT-PCR was performed to determine IL-6 and TNFa mRNA levels. (I–M: n = 5–11; *p < 0.05; **p < 0.01; ***p < 0.001). Data were expressed as
mean ± SEM.
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et al., 2010).
Tumors from both control and Stat3hep/ livers showed
typical trabecular structure of HCC (Figures 6A and 6D).
However, tumors fromShp2hep/andDKO livers lost the trabec-
ular architecture. Infiltrate of inflammatory cells was visible in the
portal triads ofShp2hep/andDKO livers (Figures 6F and6G) but
rarely observed inWTandStat3hep/portal triads. These tumors
also displayed eosin-positive cytoplasmic inclusions (Figures 6B
and 6C), and the inclusions in DKO tumors were much smaller
(Figure 6C). H&E of liver tissues showed evident fat droplets in
Stat3hep/ livers. Both Shp2hep/ and DKO animals exhibited636 Cancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc.significantly higher levels of serum ALT than controls, but ALT
levelswere lower inDKOanimals than inShp2hep/animals (Fig-
ure 6I). We also checked the hepatic inflammatory cytokines
TNFa and IL-6, and levels of both cytokines were increased in
Shp2hep/ livers, which was abolished by additional deletion
of Stat3 (Figures 6J and 6K). This result was confirmed by
qRT-PCR of IL-6 and TNFa transcripts (Figures 6L and 6M).
DISCUSSION
The results presented here indicate that selective deletion of
Ptpn11/Shp2 in hepatocytes caused hepatic inflammation and
Cancer Cell
Identification of Shp2 as a Tumor Suppressornecrosis, leading to nodular regenerative hyperplasia. The
enhanced inflammatory signaling may have promoted liver
tumorigenesis, resulting in dramatic increase of both sponta-
neous tumors and DEN-induced HCCs in Shp2hep/ mice.
Consistent with the data obtained in the animal model, we also
detected deficient/reduced Shp2 expression in 11.5% of human
HCC samples. It will be interesting to determine whether there
are deletion or point mutations at the Ptpn11/Shp2 locus in
HCC genomes that could result in functional inactivation of this
tyrosine phosphatase.
The tumor-suppressing role of Ptpn11/Shp2 in HCC is unex-
pected because our previous experiments indicated a positive
role of Shp2 in regulation of hepatocyte proliferation and growth
factor signaling through the Ras-Erk pathway by working in
concert with Gab1 adaptor protein (Bard-Chapeau et al.,
2006). Furthermore, inherited or somatic mutations in human
Ptpn11/Shp2 gene have been implicated in Noonan syndrome
or several types of leukemias, particularly JMML, thus identifying
Ptpn11 as a proto-oncogene (Chan and Feng, 2007; Tartaglia
et al., 2006). However, the inhibitory role of Shp2 on liver cancer
is very similar to the dual function of the IKK/NF-kB pathway.
Karin’s group (Maeda et al., 2005) demonstrated an inhibitory
effect of the IKKb/NF-kB pathway on DEN-induced HCC devel-
opment, in contrast to its tumor-promoting effect in colitis-asso-
ciated cancer (CAC) (Greten et al., 2004). Deletion of NEMO/
IKKg also resulted in spontaneous development of HCC in
mice (Luedde et al., 2007). He et al. (2010) demonstrated further
that deletion of IKKb in hepatocytes promoted HCC progression
through upregulation of reactive oxidative stress (ROS).
Rapidly growing evidence reinforces the notion that tumors
are promoted by inflammatory signals in the surrounding micro-
environment (Coussens and Werb, 2002; Yu et al., 2007). In this
report we show that hepatocyte-specific deletion of Shp2 re-
sulted in a marked increase of the inflammatory IL-6/Stat3 signal
strength. Consistent with this observation is the previous work
documented by us and others on a negative regulatory role of
Shp2 in Jak-Stat signaling (Bard-Chapeau et al., 2006; Chan
et al., 2003; Servidei et al., 1998; Wu et al., 2009; You et al.,
1999). Of note, we found that Shp2 ablation, while promoting
IL-6-stimulated Stat3 activation, had no effect on IkBa degrada-
tion (NF-kB activation), suggesting that Shp2 acts downstream
of, or in parallel with, NF-kB in modulation of Stat3 activity.
Indeed, a critical role of Stat3 in mediating inflammation-
provoked malignancy has been reported in several types of
cancer (Yu et al., 2009). To address the requirement for Stat3
in liver cancer elicited or enhanced by Shp2 ablation, we gener-
ated hepatocyte-specific Shp2/Stat3 DKO mice. Combined
deletion of both Shp2 and Stat3 in hepatocytes completely
alleviated the effect of Shp2 loss on HCC development, support-
ing our theory that augmented Stat3 activation plays an essential
role in hepatocarcinogenesis in Shp2hep/ mice. However, it is
also interesting to note that deletion of Stat3 in hepatocytes did
not prevent HCC development in the DEN-inducedmouse tumor
model. In fact Stat3 removal caused a modest but statistically
significant increase in DEN-induced HCC number and sizes,
compared to wild-type controls. This unexpected observation
of enhanced HCC development in Stat3hep/ mice indicates
complexity of molecular mechanisms underlying liver malig-
nancy. A body of literature documented constitutive or enhancedactivation of Stat3 in different types of cancer (He et al., 2010; Yu
et al., 2009). It will be interesting to determine why and how Stat3
deletion also exacerbates hepatocarcinogenesis.
Because tumor incidence was increased in both Shp2hep/
and Stat3hep/ mice, one would expect to observe an additive
or synergistic effect on HCC by simultaneous deletion of Shp2
and Stat3, i.e., even more severe tumor development in DKO
mice. In contrast we observed alleviation of the Shp2 deletion
effect by Stat3 removal, which indicates a distinct mechanism
of liver cancer in Stat3hep/ mice. Despite a requirement of
Stat3 for aggravated HCC development induced by Shp2 defi-
ciency, Stat3 is evidently unnecessary for liver malignancy in
this animal model. Although, to our knowledge, the mechanism
for HCC development induced by Stat3 deficiency is unknown,
results presented here suggest that Shp2 presence or absence
does not have any influence on HCC development enhanced
by Stat3 removal. Elucidating the paradoxical roles of Shp2
and Stat3, as well as several other molecules, acting as either
tumor promoter or suppressor will shed light on the molecular
basis of cancer and may suggest therapeutic strategies for the
malignant diseases.EXPERIMENTAL PROCEDURES
Mice and Liver Tumorigenesis
Hepatocyte-specific Shp2 knockout (Shp2hep/, previously called LSKO,
liver-specific Shp2 knockout) mice (C57BL/6) were generated as previously
described (Bard-Chapeau et al., 2006). Shp2flox/flox littermates were used as
control mice. Genotyping was done by PCR analysis on genomic DNA
extracted from mouse tails (Bard-Chapeau et al., 2006; Zhang et al., 2004).
Stat3flox mice were reported previously (Alonzi et al., 2001). Hepatocyte-
specific Shp2/Stat3 DKO mice were generated by crossing Shp2hep/
(Shp2flox/flox:Alb-Cre) with Stat3flox/flox mice. Genotyping of the Stat3flox allele
was done by PCR analysis on tail genomic DNA using a pair of primers (forward
50-CAC CAA CAC ATG CTA TTT GTA GG-30 and reverse 50-CCT GTC TCT
GAC AGG CCA TC-30). To determine Stat3 deletion in hepatocytes, genomic
DNA was extracted from liver using NucleaoSpin Tissue Kit. PCR was done
using a pair of primers (forward 1: 50-AGA GAG CGT CTG ACT CTA CAA
CCC T-30; forward 2: 50-GGG ATG TTG CTG CCC TCA GAG-30; reverse:
50-CAT CAA TTA GTA CAC AAA TTA CTG-30). Two forward primers (25 mM
each) and the reverse primer (50 mM) were used together to detect the Stat3D
allele.
For chemical induction of hepatocarcinogenesis, mice at postnatal day
15 were injected intraperitoneally with DEN (25 mg/kg, N0258-1G; Sigma-
Aldrich), and then weaned and maintained on regular chow food. Livers and
tumors were pictured and harvested for analysis 8months after the initial injec-
tion (He et al., 2010; Maeda et al., 2005). All animals were housed in a virus-free
facility and maintained in a temperature and light (12 hr light/dark cycle)
controlled animal facility. Mice were permitted ad libitum access to water
and standard chow. The SBMRI and UCSD Animal Use Committees approved
all protocols.
Histology and Immunostaining
Liver fixation in paraffin and H&E of 5 mm sections were performed using
standard protocols. The same slides were subjected to Masson’s trichrome
staining (Poly Scientific) or reticulin staining that was performed according to
Gordon-Sweets Reticulum Procedure (Poly Scientific). TUNEL assay was
conducted using ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit
(Chemicon), and slides were counterstained with methyl green. Liver histology
was examined by light microscopy in a blinded fashion. The extent of infiltra-
tion in parenchyma by inflammatory cells was semiquantitatively estimated by
assigning a severity score (absent, 0; mild, 1; moderate, 2; pronounced, 3;
severe, 4). This score was used to compare the liver damage and inflammation
between control and Shp2hep/ mice after LPS challenge.Cancer Cell 19, 629–639, May 17, 2011 ª2011 Elsevier Inc. 637
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Identification of Shp2 as a Tumor SuppressorAged animals drank 5-bromo-20-deoxyuridine (BrdU, 1 mg/ml, Sigma-
Aldrich, 1% sucrose, Sigma-Aldrich), and four mice in each group were
sacrificed after 2 weeks.Withdrawn livers were prepared for 5 mmcryosection-
ing and immunostaining. BrdU labeling and detection Kit I were used to stain
incorporated BrdU, and VECTASHIELD mounting medium with DAPI (Vector
Laboratories) was used to stain nuclei. BrdU-positive hepatocytes were
enumerated under fluorescent microscopy and calculated by randomly count-
ing BrdU-stained nuclei per 100 DAPI+ nuclei in a total of 2000 hepatocytes.
LPS or IL-6 Stimulation
Male animals (2- to 3-month-old littermates) were used. For 5 min stimulation
a solution of LPS (1 mg/ml in PBS; Sigma-Aldrich) was injected into the vena
cava at the dosage of 0.5 mg/25 g body weight, and livers were harvested
and quickly frozen in liquid nitrogen. For later time points, 1, 3, 14, and
24 hr, 14 days, the same solution of LPS was injected intraperitoneally at
a 4 mg/100 g body weight. Sera were collected at indicated time points, and
livers were harvested for biochemistry and histology. Under anesthesia
with Avertin (0.015 ml/g body weight), either 50 ml saline or 5 mg murine IL-6
(PeproTech Inc.) in 50 ml saline was injected into portal vein, and livers were
harvested and quickly frozen 5 min later.
Serological and Biochemical Analyses
Venous blood was collected by bleeding of the retro-orbital sinus. Serum was
separated after clotting. IL-6 and TNFa serum levels were determined by
mouse Biotrak ELISA systems (Amersham Biosciences). ALT and AST levels
in serum were measured by Animal Care Program, Diagnostic Laboratory,
University of California, San Diego. Other inflammatory cytokine amounts in
serumwere assessed using Beadlyte MouseMulti-Cytokine Detection System
Kit from Upstate or a Meso Scale Discovery Assay. ELISA on liver extracts was
performed as described previously (Cripps et al., 2010). A total of 0.12 g/ml of
liver tissue was homogenized in sucrose buffer (0.25 M sucrose, 10 mM Tris
[pH 7.4], protease inhibitor cocktail) and cleared by centrifugation (9300 3 g,
10 min).
Frozen tissue samples were processed as previously described (Bard-
Chapeau et al., 2006). Homemade antibody against Shp2 was described
previously (Feng et al., 1993). Antibodies to p-Erk1/2, p-Tyr705Stat3,
p-Ser727Stat3, Stat3, p-Stat1, p38 MAPK, p-p38 MAPK, IkBa, pAkt, and
Akt were obtained from Cell Signaling Technology, Inc. Antibodies to Erk2,
Stat1, p-Jnk1/2, and Jnk1/2 were obtained from Santa Cruz Biotechnology,
Inc. When needed, films were scanned and signals were quantified using
ImageQuant software.
Human HCC
Human liver specimens were obtained from patients with HCCwho underwent
hepatectomy or liver transplantation in Eastern Hepatobiliary Surgery Hospital,
Shanghai, China. Collection of patient samples with informed consent to an
established protocol and all experimental procedures were approved by the
Research Ethics Committee of Eastern Hepatobiliary Surgery Hospital. Tissue
sections and tissue microarrays were incubated with anti-Shp2 antibody (Cell
Signaling Technology, Inc.) at 4C overnight and then with horseradish perox-
idase-conjugated secondary antibody at 37C for 30 min. The sections were
finally incubated with diaminobenzidine and counterstained with H&E for
detection.
Statistical Analysis
Data analysis was performed using a two-tailed unpaired Student’s t test.
Values are expressed as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at doi:10.1016/j.ccr.
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